Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.

Autor: Pavlovsky C; FUNDALEU, Buenos Aires, Argentina., Vasconcelos Cordoba B; Centro de Investigaciones Oncológicas - Fundación Cáncer (CIO-FUCA), Conesa 1003, C1426DRB, Ciudad Autónoma de Buenos Aires, Argentina., Sanchez MB; Centro de Investigaciones Oncológicas - Fundación Cáncer (CIO-FUCA), Conesa 1003, C1426DRB, Ciudad Autónoma de Buenos Aires, Argentina., Moiraghi B; Hospital José María Ramos Mejía, Buenos Aires, Argentina., Varela A; Hospital José María Ramos Mejía, Buenos Aires, Argentina., Custidiano R; Instituto Alexander Fleming, Buenos Aires, Argentina., Fernandez I; FUNDALEU, Buenos Aires, Argentina., Freitas MJ; Hospital Posadas, Buenos Aires, Argentina., Ventriglia MV; Hospital Posadas, Buenos Aires, Argentina., Bendek G; Hospital Italiano, Buenos Aires, Argentina., Mariano R; Hospital San Martín, Paraná, Argentina., Mela Osorio MJ; FUNDALEU, Buenos Aires, Argentina., Pavlovsky MA; FUNDALEU, Buenos Aires, Argentina., de Labanca AG; Hospital Italiano de Mendoza, Mendoza, Argentina., Foncuberta C; Instituto Alexander Fleming, Buenos Aires, Argentina., Giere I; FUNDALEU, Buenos Aires, Argentina., Vera M; Instituto Alexander Fleming, Buenos Aires, Argentina., Juni M; FUNDALEU, Buenos Aires, Argentina., Mordoh J; Centro de Investigaciones Oncológicas - Fundación Cáncer (CIO-FUCA), Conesa 1003, C1426DRB, Ciudad Autónoma de Buenos Aires, Argentina., Sanchez Avalos JC; Instituto Alexander Fleming, Buenos Aires, Argentina., Cueto G; Instituto de Ecología, Genética y Evolución de Buenos Aires, Buenos Aires, Argentina., Miranda S; Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET, CONICET-UBA), Buenos Aires, Argentina., Levy EM; Centro de Investigaciones Oncológicas - Fundación Cáncer (CIO-FUCA), Conesa 1003, C1426DRB, Ciudad Autónoma de Buenos Aires, Argentina., Bianchini M; Centro de Investigaciones Oncológicas - Fundación Cáncer (CIO-FUCA), Conesa 1003, C1426DRB, Ciudad Autónoma de Buenos Aires, Argentina. mbianchini@conicet.gov.ar.
Jazyk: angličtina
Zdroj: Journal of hematology & oncology [J Hematol Oncol] 2023 Apr 29; Vol. 16 (1), pp. 43. Date of Electronic Publication: 2023 Apr 29.
DOI: 10.1186/s13045-023-01440-6
Abstrakt: Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1 low /IL-6 low patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje